Assessment of multidrug-resistant tuberculosis (MDR-TB) treatment outcomes in Sudan; findings and implications

References

• WHO. Global tuberculosis report executive summary 2019. [cited 2019 Oct 28]. Available from: URL:https://www.who.int/tb/publications/global_report/tb19_Exec_Sum_15October2019.pdf?ua=1.
   Google Scholar
• WHO. Global tuberculosis report (full). 2019. [cited 2019 Oct 28]. Available from: URL:https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf?ua=1
   Google Scholar
• Seaworth BJ, Griffith DE. Therapy of multidrug-resistant and extensively drug-resistant tuberculosis. Microbiol Spectr. 2017;5:2.
   Google Scholar
• Dheda K, Chang KC, Guglielmetti L, et al. Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Microbiol Infect. 2017;23(3):131–140.
   PubMed Web of Science ®Google Scholar
• Kapata N, Grobusch MP, Chongwe G, et al. Outcomes of multidrug-resistant tuberculosis in Zambia: a cohort analysis. Infection. 2017;45(6):831–839.
   PubMed Web of Science ®Google Scholar
• WHO. GLOBAL TUBERCULOSIS REPORT. 2016. [cited 2019 Jun 1]. Available from URL:http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-eng.pdf?ua=1
   Google Scholar
• WHO. Global Tuberculosis Report. 2018. [cited 2019 Jun 2]. Available from: http://apps.who.int/iris/bitstream/handle/10665/274453/9789241565646-eng.pdf?ua=1
   Google Scholar
• Riccardi N, Alagna R, Saderi L, et al. Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres. BMC Infect Dis. 2019;19(1):564.
   PubMed Web of Science ®Google Scholar
• Pooran A, Pieterson E, Davids M, et al. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PloS One. 2013;8(1):e54587.
   PubMed Web of Science ®Google Scholar
• WHO. Drug-Resistant TB Surveillance & Response. Supplement to Global Tuberculosis Report 2014. Available at URL:http://apps.who.int/medicinedocs/en/m/abstract/Js21635en/
   Google Scholar
• WHO. MULTIDRUG-RESISTANT TUBERCULOSIS (MDR-TB). 2018. [cited 2019 Oct 28]. Available from: URL:https://www.who.int/tb/areas-of-work/drug-resistant-tb/MDR-RR_TB_factsheet_2018_Apr2019.pdf?ua=1
   Google Scholar
• Dean AS, Cox H, Zignol M. Epidemiology of Drug-Resistant Tuberculosis. Adv Exp Med Biol. 2017;1019:209–220.
   PubMed Web of Science ®Google Scholar
• Wilson JW, Tsukayama DT. Extensively drug-resistant tuberculosis: principles of resistance, diagnosis, and management. Mayo Clin Proc. 2016;91(4):482–495.
   PubMed Web of Science ®Google Scholar
• Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9(8):e1001300.
   PubMed Web of Science ®Google Scholar
• Ormerod LP. Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. Br Med Bull. 2005;73–74(1):17–24.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis 2011. [cited 2019 Jun 2]. Available from: URL:https://apps.who.int/iris/bitstream/handle/10665/44597/9789241501583_eng.pdf;jsessionid=A09557FE3108BD00C5B0C8C604DE4127?sequence=1
   Google Scholar
• Stop TB partnership. The global plan to stop TB 2011–2015. [cited 2019 Oct 29]. Available from: URL:http://www.stoptb.org/assets/documents/global/plan/TB_GlobalPlanToStopTB2011-2015.pdf
   Google Scholar
• WHO. WHO updates its treatment guidelines for multidrug- and rifampicin-resistant tuberculosis. 2018. [cited 2019 Oct 29]. Available from: URL:https://www.who.int/tb/features_archive/updated-treatment-guidelines-multigrug-rifampicin-resistant-TB/en/
   Google Scholar
• World Health Organization. Guidelines for establishing DOTS-Plus pilot projects for the management of multidrug-resistant tuberculosis (MDR-TB). 2000. [cited 2019 May 30]. Available from: URL:https://apps.who.int/iris/bitstream/handle/10665/66368/WHO_CDS_TB_2000.279.pdf;jsessionid=883E3D89810A0FEC391F729F6062DC4F?sequence=1
   Google Scholar
• Nagaraja C, Shashibhushan BL, Asif M, et al. Pattern of drug-resistance and treatment outcome in multidrug-resistant pulmonary tuberculosis. Indian J Chest Dis Allied Sci. 2012;54(1):23–26.
   PubMedGoogle Scholar
• Kurbatova EV, Cegielski JP, Lienhardt C, et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respir Med. 2015;3(3):201–209.
   PubMed Web of Science ®Google Scholar
• Kurbatova EV, Gammino VM, Bayona J, et al. Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2012;16(10):1335–1343.
   PubMed Web of Science ®Google Scholar
• Adam MAM, Ali HMH, Khalil EAG. Initial second-line drug resistance of Mycobacterium tuberculosis isolates from Sudanese retreatment-patients. J Clin Tuberculosis Other Mycobacterial Dis. 2017;9:21–23.
   PubMedGoogle Scholar
• Sharaf Eldin GS, Fadl-Elmula I, Ali MS, et al. Tuberculosis in Sudan: a study of Mycobacterium tuberculosis strain genotype and susceptibility to anti-tuberculosis drugs. BMC Infect Dis. 2011;11(1):219.
   PubMedGoogle Scholar
• Cameron A, Ewen M, Ross-Degnan D, et al. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009;373(9659):240–249.
   PubMed Web of Science ®Google Scholar
• Basit A, Ahmad N, Khan AH, et al. Predictors of two months culture conversion in multidrug-resistant tuberculosis: findings from a retrospective cohort study. Plos One. 2014;9(4):e93206.
   PubMed Web of Science ®Google Scholar
• Liu Q, Lu P, Martinez L, Yang H, Lu W, Ding X, et al. Factors affecting time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis in China. BMC Infect Dis. 2018;18(1):114.
   PubMedGoogle Scholar
• Melese A, Zeleke B. Factors associated with poor treatment outcome of tuberculosis in Debre Tabor, northwest Ethiopia. BMC Res Notes. 2018;11(1):25.
   PubMedGoogle Scholar
• Jeon DS, Shin DO, Park SK, et al. Treatment outcome and mortality among patients with multidrug-resistant tuberculosis in tuberculosis hospitals of the public sector. J Korean Med Sci. 2011;26(1):33–41.
   PubMed Web of Science ®Google Scholar
• Meressa D, Hurtado RM, Andrews JR, et al. Achieving high treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia–an observational cohort study. Thorax. 2015;70(12):1181–1188.
   PubMed Web of Science ®Google Scholar
• Getachew T, Bayray A, Weldearegay B. Survival and predictors of mortality among patients under multi-drug resistant tuberculosis treatment in Ethiopia: St. Peter’s Specialized Tuberculosis Hospital, Ethiopia. Int J Pharm Sci Res. 2013;4(2):776–787.
   Google Scholar
• IAMAT. Sudan for specific travellers: tuberculosis. 2017. [cited 2019 May 28]. Available from: URL:https://www.iamat.org/country/sudan/risk/tuberculosis
   Google Scholar
• Elmadhoun WM, Noor SK, Bushara SO, et al. Epidemiology of tuberculosis and evaluation of treatment outcomes in the national tuberculosis control programme, River Nile state, Sudan, 2011–2013. East Mediterr Health J. 2016;22(2):95–102.
   PubMed Web of Science ®Google Scholar
• Hassanain SA, Edwards JK, Venables E, et al. Conflict and tuberculosis in Sudan: a 10-year review of the national tuberculosis programme, 2004–2014. Confl Health. 2018;12:18.
   PubMed Web of Science ®Google Scholar
• Ali AOA, Prins MH. Disease and treatment-related factors associated with tuberculosis treatment default in Khartoum State, Sudan: a case-control study. East Mediterr Health J. 2017;23(6):408–414.
   PubMed Web of Science ®Google Scholar
• Lange C, Abubakar I, Alffenaar J-WC, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J. 2014;44(1):23–63.
   PubMed Web of Science ®Google Scholar
• Geissler PW, Nokes K, Prince RJ, et al. Children and medicines: self-treatment of common illnesses among Luo schoolchildren in western Kenya. Soc Sci Med. 2000;50(12):1771–1783.
   Web of Science ®Google Scholar
• Sudan national TB management guideline 2019. [cited 2019 Oct 28]. Available from: URL:https://www.humanitarianresponse.info/sites/www.humanitarianresponse.info/files/2019/07/Sudan-National-TB-management-Guideline-March.2019-1.pdf
   Google Scholar
• WHO Guidelines approved by the guidelines review committee. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva: World Health Organization; 2014.
   Google Scholar
• Alene KA, Viney K, McBryde ES, et al. Treatment outcomes in patients with multidrug-resistant tuberculosis in north-west Ethiopia. Trop Med Int Health. 2017;22(3):351–362.
   PubMed Web of Science ®Google Scholar
• Dhavan P, Dias HM, Creswell J, et al. An overview of tuberculosis and migration. Int J Tuberculosis Lung Dis. 2017;21(6):610–623.
   PubMed Web of Science ®Google Scholar
• Gadallah MA, Mokhtar A, Rady M, et al. Prognostic factors of treatment among patients with multidrug-resistant tuberculosis in Egypt. J Formosan Med Assoc. 2016;115(11):997–1003.
   PubMed Web of Science ®Google Scholar
• Khan I, Ahmad N, Khan S, et al. Evaluation of treatment outcomes and factors associated with unsuccessful outcomes in multidrug resistant tuberculosis patients in Baluchistan province of Pakistan. J Infect Public Health. 2019;12:809–815.
   Web of Science ®Google Scholar
• Marks SM, Flood J, Seaworth B, et al. Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005–2007. Emerg Infect Dis. 2014;20(5):812–821.
   PubMed Web of Science ®Google Scholar
• Peter Helblinga EA, Eggerb J-M, Zellweger, J-P. Treatment outcomes of multidrug-resistant tuberculosis in Switzerland. Swiss Med Wkly. 2014;144:w14053.
   PubMed Web of Science ®Google Scholar
• Ebrahim EM, Ghebrehiwot L, Abdalgfar T, et al. Health care system in Sudan: review and analysis of strength, weakness, opportunity, and threats (SWOT Analysis). Sudan J Med Sci. 2017;12(3):133–150.
   Web of Science ®Google Scholar
• Nashilongo MM, Singu B, Kalemeera F, et al. Assessing adherence to antihypertensive therapy in primary health care in Namibia: findings and implications. Cardiovasc Drugs Ther. 2017;31(5–6):565–578.
   PubMed Web of Science ®Google Scholar
• Ambaw AD, Alemie GA, Yohannes SM, et al. Adherence to antihypertensive treatment and associated factors among patients on follow up at University of Gondar Hospital, Northwest Ethiopia. BMC Public Health. 2012;12:282.
   PubMed Web of Science ®Google Scholar
• Ahmed OA, Ali MHP. Disease and treatment-related factors associated with tuberculosis treatment default in Khartoum State, Sudan: a case–control study. East Mediterr Health J. 2017;23(6):408–414.
   PubMed Web of Science ®Google Scholar
• Chen M-Y, Lo Y-C, Chen W-C, et al. Recurrence after successful treatment of multidrug-resistant tuberculosis in Taiwan. PloS One. 2017;12(1):e0170980–e.
   PubMed Web of Science ®Google Scholar
• Espinal MA, Laserson K, Camacho M, et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis. 2001;5(10):887–893.
   PubMed Web of Science ®Google Scholar
• Mirsaeidi SM, Tabarsi P, Khoshnood K, et al. Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran. Inter J Infect Dis. 2005;9(6):317–322.
   PubMed Web of Science ®Google Scholar
• Sampurna Kakchapati BNG, Rakesh Kumar J. Chamnein choonpradub. Treatment outcome of multidrug-resistant mycobacterium tuberculosis in Nepal. Asia-Pac J Public Health. 2012;24(4):631–640.
   PubMed Web of Science ®Google Scholar
• Charles M, Vilbrun SC, Koenig SP, et al. Treatment outcomes for patients with multidrug-resistant tuberculosis in post-earthquake Port-au-Prince, Haiti. Am J Trop Med Hyg. 2014;91(4):715–721.
   PubMed Web of Science ®Google Scholar
• Isanaka S, Mugusi F, Urassa W, et al. Iron deficiency and anemia predict mortality in patients with tuberculosis. J Nutr. 2012;142(2):350–357.
   PubMed Web of Science ®Google Scholar
• Kourbatova EV, Borodulin BE, Borodulina EA, et al. Risk factors for mortality among adult patients with newly diagnosed tuberculosis in Samara, Russia. Int J Tuberc Lung Dis. 2006;10(11):1224–1230.
   PubMed Web of Science ®Google Scholar
• Dalton T, Cegielski P, Akksilp S, et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet. 2012;380(9851):1406–1417.
   PubMed Web of Science ®Google Scholar
• Kurbatova EV, Taylor A, Gammino VM, et al. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis.(2012);92:397–403.
   PubMed Web of Science ®Google Scholar
• Patel SV, Nimavat KB, Alpesh PB, et al. Treatment outcome among cases of multidrug-resistant tuberculosis (MDR TB) in Western India: A prospective study. J Infect Public Health. 2016;9(4):478–484.
   PubMed Web of Science ®Google Scholar
• MdS G, Penna ML, Perez-Porcuna TM, et al. Factors associated with tuberculosis treatment default in an endemic area of the Brazilian Amazon: A case control-study. Plos One. 2012;7(6):e39134.
   PubMed Web of Science ®Google Scholar
• Girum T, Tariku Y, Survival Status DS. Treatment outcome of Multidrug Resistant Tuberculosis (MDR-TB) among patients treated in Treatment Initiation Centers (TIC) in South Ethiopia: A retrospective cohort study. Ann Med Health Sci Res. 2017;7(5):331–336.
   Web of Science ®Google Scholar
• Waitt CJ, Squire SB. A systematic review of risk factors for death in adults during and after tuberculosis treatment. [Review article]. Int J Tuberc Lung Dis. 2011;15(7):871–885.
   PubMed Web of Science ®Google Scholar
• Ramachandran G, Swaminathan S. Safety and tolerability profile of second-line anti-tuberculosis medications. Drug Saf. 2015;38(3):253–269.
   PubMed Web of Science ®Google Scholar